CPAP Improves the Walking Capacity in Patients With COPD and OSA
1 other identifier
interventional
60
1 country
1
Brief Summary
We have reported that CPAP treatment improved the walking capacity of overlap syndrome patients. However, the previous study was not randomized, double blinded study. Therefore, we design a prospective, randomized, double blinded, controlled, cross-over trial to confirm this finding.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2013
CompletedFirst Submitted
Initial submission to the registry
July 28, 2013
CompletedFirst Posted
Study publicly available on registry
August 5, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2016
CompletedNovember 22, 2016
April 1, 2013
3.6 years
July 28, 2013
November 20, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
exercise capacity (walking distance (meter), measured by incremental shuttle walking test)
CPAP treatment for 1 month
Study Arms (2)
group A
ACTIVE COMPARATORgroup A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement
group B
SHAM COMPARATORgroup B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
Interventions
Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
Eligibility Criteria
You may qualify if:
- FEV1/FVC \< 70%, no response to bronchodilator (FEV1 change \<12% and \<200ml)
- OSA : AHI \> 15/h, obstructive type predominant
You may not qualify if:
- any malignancy
- pregnancy
- claustrophobia
- age\<18
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Thoracic Medicine, Chang Gung Memorial Hospital
Taipei, Taiwan
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
TSAI-YU WANG, MD
Department of Thoracic Medicine, Chang Gung Memorial Hospital 199 Tun-Hwa N. Rd., Taipei, Taiwan
- PRINCIPAL INVESTIGATOR
TSAI-YU WANG, MD
Department of Thoracic Medicine, Chang Gung Memorial Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 28, 2013
First Posted
August 5, 2013
Study Start
April 1, 2013
Primary Completion
November 1, 2016
Last Updated
November 22, 2016
Record last verified: 2013-04